

REMARKS

The specification has been amended to correct a typographical error. As the effervescent tablet is described at page 5, lines 5-7 of the specification as "Group A" and the solution prepared from Lyoc is described at page 5, lines 9-11 as "Group C" the amendment at page 5, lines 15-16 is in accordance with the previous disclosure, and no new matter has been added.

The claims have been amended to delete all multiple dependencies, and to generally place the claims in better form for US practice.

Attached is the search report of the corresponding PCT application, together with copies of the references cited therein, which are listed on the attached Form PTO-1449.

Respectfully submitted,



Ira J. Schultz
Registration No. 28666

APPENDIX

IN THE SPECIFICATION:

Page 5, lines 15-16:

Group [A] C: Lyoc: 28% (not significant relative to the controls (Group B))

Group [C] A: Effervescent compound: 47% (significant at p > 0.001)

IN THE CLAIMS:

1. (Amended) Pharmaceutical [compositions] composition for [the] oral administration of phloroglucinol, [characterized in that, when liquid, they contain] comprising, in a liquid state, a system which buffers [them] the composition to a pH of between 3 and 7, or [in that, when solid, they contain] in a solid state, a system which, when [they are] placed in an aqueous medium, is capable of [exerting] providing a buffer effect between pH 3 and pH 7.

2. (Amended) Pharmaceutical [compositions] composition according to claim 1, [characterized in that] wherein said buffer pH is between 4 and 6.

3. (Amended) Pharmaceutical [compositions] composition according to claim 1 [or 2], [characterized in that they are presented] in the form of solutions, suspensions or syrups or in the form of tablets, gelatin capsules, powders, granules or lyophilizates.

4. (Amended) Pharmaceutical [compositions] composition according to [any one of claims 1 to 3, characterized in that] claim 1, wherein said system responsible for the buffer effect comprises at least one organic acid and/or at least one salt of an organic acid in association with at least one strong base and/or at least one salt of a strong base.

5. (Amended) Pharmaceutical [compositions] composition according to claim 4, [characterized in that] wherein said organic acid is selected from the group consisting of citric, tartaric, malic, lactic, acetic, glutaric, benzoic and adipic acids.

6. (Amended) Pharmaceutical [compositions] composition according to claim 4 [or 5], [characterized in that] wherein said base [takes the form of] comprises sodium bicarbonate, sodium carbonate, calcium carbonate, magnesium carbonate, sodium hydroxide, potassium hydroxide, potassium bicarbonate or potassium carbonate.

7. (Amended) Pharmaceutical [compositions] composition according to [any one of claims 1 to 6, characterized in that they are presented] claim 1, in the form of an effervescent solid galenical [preparations] preparation.

8. (Amended) Pharmaceutical [compositions] composition according to [any one of claims 1 to 7, characterized in that they are presented] claim 1, in the form of an effervescent

[tablets] tablet.

9. (Amended) Pharmaceutical [compositions] composition according to [any one of claims 1 to 7, characterized in that they are presented] claim 1, in the form of an effervescent [tablets] tablet containing citric acid and sodium bicarbonate.

10. (Amended) Process for the preparation of a pharmaceutical [compositions] composition according to [any one of the preceding claims, characterized in that it comprises] claim 1, comprising formulating the phloroglucinol in [the] a liquid form with a system which buffers said liquid form to a pH of between 3 and 7, or in [the] a solid form with a system which, when said solid form is placed in an aqueous medium, is capable of [exerting] providing a buffer effect between pH 3 and pH 7.